Law Office of Brodsky & Smith, LLC Announces Investigation of
MAP Pharmaceuticals, Inc.
BALA CYNWYD, Pa., Jan. 23, 2013 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of MAP
Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ-NMS: MAPP)
relating to the proposed acquisition by Allergan, Inc.
("Allergan").
Under the terms of the transaction, MAP shareholders will
receive only $25.00 in cash for each
share of MAP stock they own. The investigation concerns possible
breaches of fiduciary duty and other violations of state law by the
Board of Directors of MAP for not acting in the Company's
shareholders' best interests in connection with the sale process to
Allergan. MAP is expected to receive a decision on its inhalable
migraine treatment Levadex by the Food and Drug Administration
before mid-April. It has been reported that the global migraine
drug market will reach $5.8 billion
by 2021.
If you own shares of MAP stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L.
Brodsky, Esquire or Evan J. Smith,
Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by
e-mail at investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/530-mapp-map-pharmaceuticals-inc.html, by
calling toll free 877-LEGAL-90.
SOURCE Brodsky & Smith, LLC